Moorfields Eye Hospital to Open Eye Care Diagnostic Hub at Brent Cross United Kingdom

Hammerson and Aberdeen Standard Investments (“Aberdeen”), joint owners of the flagship destination Brent Cross, announce that Moorfields Eye Hospital is to open its latest diagnostic hub at the destination. The facility, which opens in September, will be Moorfields’ third diagnostic hub outside of its central London hospital.

Moorfields will be taking 15,000 sq ft of space across two floors, in a unit previously occupied by New Look. The agreement is the latest example of how Hammerson, as joint owner and asset manager, is collaborating with businesses and public sector partners to repurpose retail space for alternative uses, including the creation of wellness and community services. The Moorfields hub will benefit from the destination’s easy access via road and public transport and unique role at the heart of the local community.

The hub will offer a monitoring service for existing Moorfields patients with retinal problems or glaucoma – two of the leading causes of preventable sight loss in the United Kingdom. Instead of having to wait to see a doctor, an appointment at the diagnostic hub aims to take patients through a series of rapid tests in around 45 minutes, allowing more patients to be seen.

These test results are then reviewed online by senior consultants who will contact patients about test outcomes and any next steps. In partnership with the National Institute for Health Research Moorfields Biomedical Research Centre and UCL, Moorfields staff will explore innovative new methods of improving efficiency.

Iain Mitchell, UK Commercial Director at Hammerson commented, “Across our portfolio, we are constantly looking at how we can respond to evolving consumer needs, and innovate and enhance our destinations. Over the last year, we have seen how important access to healthcare services is to our communities, and Brent Cross’s easily accessible location and free parking will provide a convenient and safe way for patients to access medical eye care.

The decision by Moorfields to launch its first diagnostic hub within a retail destination is the latest example of how we are repurposing spaces, diversifying the tenant mix and creating vibrant destinations which serve local communities.”

Louisa Wickham, Medical Director at Moorfields Eye Hospital added, “This new diagnostic hub at Brent Cross is a unique opportunity to provide medical eye testing to our patients in a convenient location. Our diagnostic hubs have already proved very popular with patients, and opening another allows more of them to access these services.”

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version